Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.2
(4.81%)
HKD 0.2
(4.81%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -138.53 Million CNY | 94.35% |
| 2022 | -2.45 Billion CNY | 59.26% |
| 2021 | -6.01 Billion CNY | -557.07% |
| 2020 | -915.87 Million CNY | -1454.56% |
| 2019 | -58.91 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -47.56 Million CNY | 87.95% |
| 2024 Q2 | -47.56 Million CNY | 0.0% |
| 2023 FY | -138.53 Million CNY | 94.35% |
| 2023 Q2 | 325.31 Million CNY | 0.0% |
| 2023 Q1 | 325.31 Million CNY | 149.45% |
| 2023 Q4 | -394.58 Million CNY | 0.0% |
| 2023 Q3 | -394.58 Million CNY | -221.29% |
| 2022 Q2 | -568.04 Million CNY | 0.0% |
| 2022 Q1 | -568.04 Million CNY | 75.84% |
| 2022 FY | -2.45 Billion CNY | 59.26% |
| 2022 Q4 | -657.9 Million CNY | 0.0% |
| 2022 Q3 | -657.9 Million CNY | -15.82% |
| 2021 Q2 | -657.37 Million CNY | 0.0% |
| 2021 FY | -6.01 Billion CNY | -557.07% |
| 2021 Q4 | -2.35 Billion CNY | 0.0% |
| 2021 Q3 | -2.35 Billion CNY | -257.6% |
| 2021 Q1 | -657.37 Million CNY | 0.0% |
| 2020 FY | -915.87 Million CNY | -1454.56% |
| 2019 FY | -58.91 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 295.467% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 903.125% |